Diagnosis  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
treatment  ||| S:14 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
attention  ||| S:27 E:37 ||| NN
deficit  ||| S:37 E:45 ||| NN
hyperactivity  ||| S:45 E:59 ||| NN
disorder  ||| S:59 E:68 ||| NN
in  ||| S:68 E:71 ||| IN
adults  ||| S:71 E:78 ||| NNS
To  ||| S:78 E:81 ||| TO
review  ||| S:81 E:88 ||| VB
the  ||| S:88 E:92 ||| DT
latest  ||| S:92 E:99 ||| JJS
data  ||| S:99 E:104 ||| NNS
available  ||| S:104 E:114 ||| JJ
concerning  ||| S:114 E:125 ||| VBG
the  ||| S:125 E:129 ||| DT
diagnosis  ||| S:129 E:139 ||| NN
and  ||| S:139 E:143 ||| CC
treatment  ||| S:143 E:153 ||| NN
of  ||| S:153 E:156 ||| IN
adults  ||| S:156 E:163 ||| NNS
with  ||| S:163 E:168 ||| IN
attention  ||| S:168 E:178 ||| NN
deficit  ||| S:178 E:186 ||| NN
hyper-activity  ||| S:186 E:201 ||| JJ
disorder  ||| S:201 E:210 ||| NN
( ||| S:210 E:211 ||| -LRB-
ADHD ||| S:211 E:215 ||| NNP
) ||| S:215 E:216 ||| -RRB-
.  ||| S:216 E:218 ||| .
A  ||| S:218 E:220 ||| DT
number  ||| S:220 E:227 ||| NN
of  ||| S:227 E:230 ||| IN
different  ||| S:230 E:240 ||| JJ
instruments  ||| S:240 E:252 ||| NNS
for  ||| S:252 E:256 ||| IN
evaluating  ||| S:256 E:267 ||| VBG
ADHD  ||| S:267 E:272 ||| NNS
have  ||| S:272 E:277 ||| VBP
been  ||| S:277 E:282 ||| VBN
adapted  ||| S:282 E:290 ||| VBN
to  ||| S:290 E:293 ||| TO
the  ||| S:293 E:297 ||| DT
adult  ||| S:297 E:303 ||| NN
patient  ||| S:303 E:311 ||| NN
and  ||| S:311 E:315 ||| CC
allow  ||| S:315 E:321 ||| VB
a  ||| S:321 E:323 ||| DT
reliable  ||| S:323 E:332 ||| JJ
diagnosis  ||| S:332 E:342 ||| NN
of  ||| S:342 E:345 ||| IN
the  ||| S:345 E:349 ||| DT
disorder  ||| S:349 E:358 ||| NN
to  ||| S:358 E:361 ||| TO
be  ||| S:361 E:364 ||| VB
reached ||| S:364 E:371 ||| VBN
.  ||| S:371 E:373 ||| .
Semi-structured  ||| S:373 E:389 ||| JJ
interviews ||| S:389 E:399 ||| NNS
,  ||| S:399 E:401 ||| ,
like  ||| S:401 E:406 ||| IN
the  ||| S:406 E:410 ||| DT
Diagnostisch  ||| S:410 E:423 ||| NNP
Interview  ||| S:423 E:433 ||| NNP
Voor  ||| S:433 E:438 ||| NNP
ADHD  ||| S:438 E:443 ||| NNP
2.0  ||| S:443 E:447 ||| NNP
( ||| S:447 E:448 ||| -LRB-
DIVA ||| S:448 E:452 ||| NNP
) ||| S:452 E:453 ||| -RRB-
,  ||| S:453 E:455 ||| ,
simplify  ||| S:455 E:464 ||| VBG
the  ||| S:464 E:468 ||| DT
task  ||| S:468 E:473 ||| NN
of  ||| S:473 E:476 ||| IN
performing  ||| S:476 E:487 ||| VBG
a  ||| S:487 E:489 ||| DT
rigorous  ||| S:489 E:498 ||| JJ
evaluation  ||| S:498 E:509 ||| NN
of  ||| S:509 E:512 ||| IN
both  ||| S:512 E:517 ||| PDT
the  ||| S:517 E:521 ||| DT
symptoms  ||| S:521 E:530 ||| NNS
of  ||| S:530 E:533 ||| IN
the  ||| S:533 E:537 ||| DT
disorder  ||| S:537 E:546 ||| NN
in  ||| S:546 E:549 ||| IN
adulthood  ||| S:549 E:559 ||| NN
and  ||| S:559 E:563 ||| CC
the  ||| S:563 E:567 ||| DT
dysfunctions  ||| S:567 E:580 ||| NN
generated  ||| S:580 E:590 ||| VBD
by  ||| S:590 E:593 ||| IN
ADHD ||| S:593 E:597 ||| NNP
.  ||| S:597 E:599 ||| .
Quick  ||| S:599 E:605 ||| JJ
screening  ||| S:605 E:615 ||| NN
instruments  ||| S:615 E:627 ||| NNS
that  ||| S:627 E:632 ||| WDT
allow  ||| S:632 E:638 ||| VBP
better  ||| S:638 E:645 ||| JJR
detection  ||| S:645 E:655 ||| NN
of  ||| S:655 E:658 ||| IN
ADHD  ||| S:658 E:663 ||| NNP
in  ||| S:663 E:666 ||| IN
adults ||| S:666 E:672 ||| NNS
,  ||| S:672 E:674 ||| ,
such  ||| S:674 E:679 ||| JJ
as  ||| S:679 E:682 ||| IN
the  ||| S:682 E:686 ||| DT
Adult  ||| S:686 E:692 ||| NNP
Self-Report  ||| S:692 E:704 ||| NNP
Scale  ||| S:704 E:710 ||| NNP
1.1  ||| S:710 E:714 ||| CD
( ||| S:714 E:715 ||| -LRB-
ASRS ||| S:715 E:719 ||| NNP
) ||| S:719 E:720 ||| -RRB-
,  ||| S:720 E:722 ||| ,
have  ||| S:722 E:727 ||| VBP
been  ||| S:727 E:732 ||| VBN
validated ||| S:732 E:741 ||| NN
.  ||| S:741 E:743 ||| .
In  ||| S:743 E:746 ||| IN
recent  ||| S:746 E:753 ||| JJ
years ||| S:753 E:758 ||| NNS
,  ||| S:758 E:760 ||| ,
there  ||| S:760 E:766 ||| EX
has  ||| S:766 E:770 ||| VBZ
been  ||| S:770 E:775 ||| VBN
a  ||| S:775 E:777 ||| DT
notable  ||| S:777 E:785 ||| JJ
increase  ||| S:785 E:794 ||| NN
in  ||| S:794 E:797 ||| IN
the  ||| S:797 E:801 ||| DT
number  ||| S:801 E:808 ||| NN
of  ||| S:808 E:811 ||| IN
studies  ||| S:811 E:819 ||| NNS
focused  ||| S:819 E:827 ||| VBN
on  ||| S:827 E:830 ||| IN
ADHD  ||| S:830 E:835 ||| NNP
in  ||| S:835 E:838 ||| IN
adults  ||| S:838 E:845 ||| NNS
and  ||| S:845 E:849 ||| CC
that  ||| S:849 E:854 ||| DT
research  ||| S:854 E:863 ||| NN
has  ||| S:863 E:867 ||| VBZ
provided  ||| S:867 E:876 ||| VBN
solid  ||| S:876 E:882 ||| JJ
data  ||| S:882 E:887 ||| NNS
regarding  ||| S:887 E:897 ||| VBG
the  ||| S:897 E:901 ||| DT
safety  ||| S:901 E:908 ||| NN
and  ||| S:908 E:912 ||| CC
effectiveness  ||| S:912 E:926 ||| NN
of  ||| S:926 E:929 ||| IN
different  ||| S:929 E:939 ||| JJ
treatments ||| S:939 E:949 ||| NNS
.  ||| S:949 E:951 ||| .
According  ||| S:951 E:961 ||| VBG
to  ||| S:961 E:964 ||| TO
the  ||| S:964 E:968 ||| DT
recommendations  ||| S:968 E:984 ||| NNS
of  ||| S:984 E:987 ||| IN
the  ||| S:987 E:991 ||| DT
European  ||| S:991 E:1000 ||| JJ
Consensus  ||| S:1000 E:1010 ||| JJ
statement  ||| S:1010 E:1020 ||| NN
by  ||| S:1020 E:1023 ||| IN
the  ||| S:1023 E:1027 ||| DT
European  ||| S:1027 E:1036 ||| NNP
Network  ||| S:1036 E:1044 ||| NNP
Adult  ||| S:1044 E:1050 ||| NNP
ADHD ||| S:1050 E:1054 ||| NNP
,  ||| S:1054 E:1056 ||| ,
the  ||| S:1056 E:1060 ||| DT
treatment  ||| S:1060 E:1070 ||| NN
ought  ||| S:1070 E:1076 ||| MD
to  ||| S:1076 E:1079 ||| TO
be  ||| S:1079 E:1082 ||| VB
multimodal ||| S:1082 E:1092 ||| NNS
,  ||| S:1092 E:1094 ||| ,
which  ||| S:1094 E:1100 ||| WDT
means  ||| S:1100 E:1106 ||| VBZ
combining  ||| S:1106 E:1116 ||| VBG
pharmacological  ||| S:1116 E:1132 ||| JJ
interventions  ||| S:1132 E:1146 ||| NNS
with  ||| S:1146 E:1151 ||| IN
psychological  ||| S:1151 E:1165 ||| JJ
and  ||| S:1165 E:1169 ||| CC
psychosocial  ||| S:1169 E:1182 ||| JJ
ones ||| S:1182 E:1186 ||| NNS
.  ||| S:1186 E:1188 ||| .
Methylphenidate  ||| S:1188 E:1204 ||| JJ
displays  ||| S:1204 E:1213 ||| NNS
a  ||| S:1213 E:1215 ||| DT
high  ||| S:1215 E:1220 ||| JJ
degree  ||| S:1220 E:1227 ||| NN
of  ||| S:1227 E:1230 ||| IN
effectiveness  ||| S:1230 E:1244 ||| NN
and  ||| S:1244 E:1248 ||| CC
safety  ||| S:1248 E:1255 ||| NN
in  ||| S:1255 E:1258 ||| IN
the  ||| S:1258 E:1262 ||| DT
treatment  ||| S:1262 E:1272 ||| NN
of  ||| S:1272 E:1275 ||| IN
adults  ||| S:1275 E:1282 ||| NNS
at  ||| S:1282 E:1285 ||| IN
doses  ||| S:1285 E:1291 ||| NNS
of  ||| S:1291 E:1294 ||| IN
around  ||| S:1294 E:1301 ||| IN
1  ||| S:1301 E:1303 ||| CD
mg ||| S:1303 E:1305 ||| CD
/ ||| S:1305 E:1306 ||| CD
kg ||| S:1306 E:1308 ||| CD
/ ||| S:1308 E:1309 ||| CD
day ||| S:1309 E:1312 ||| NN
.  ||| S:1312 E:1314 ||| .
Amphetamines ||| S:1314 E:1326 ||| NNP
,  ||| S:1326 E:1328 ||| ,
such  ||| S:1328 E:1333 ||| JJ
as  ||| S:1333 E:1336 ||| IN
lisdexamphetamine ||| S:1336 E:1353 ||| NN
,  ||| S:1353 E:1355 ||| ,
have  ||| S:1355 E:1360 ||| VBP
also  ||| S:1360 E:1365 ||| RB
proved  ||| S:1365 E:1372 ||| VBN
to  ||| S:1372 E:1375 ||| TO
be  ||| S:1375 E:1378 ||| VB
effective  ||| S:1378 E:1388 ||| JJ
in  ||| S:1388 E:1391 ||| IN
the  ||| S:1391 E:1395 ||| DT
treatment  ||| S:1395 E:1405 ||| NN
of  ||| S:1405 E:1408 ||| IN
adults  ||| S:1408 E:1415 ||| NNS
with  ||| S:1415 E:1420 ||| IN
ADHD ||| S:1420 E:1424 ||| NNP
.  ||| S:1424 E:1426 ||| .
Among  ||| S:1426 E:1432 ||| IN
non-stimulant  ||| S:1432 E:1446 ||| JJ
treatments ||| S:1446 E:1456 ||| NNS
,  ||| S:1456 E:1458 ||| ,
atomoxetine  ||| S:1458 E:1470 ||| NN
has  ||| S:1470 E:1474 ||| VBZ
proved  ||| S:1474 E:1481 ||| VBN
to  ||| S:1481 E:1484 ||| TO
be  ||| S:1484 E:1487 ||| VB
effective  ||| S:1487 E:1497 ||| JJ
and  ||| S:1497 E:1501 ||| CC
safe  ||| S:1501 E:1506 ||| JJ
in  ||| S:1506 E:1509 ||| IN
adults  ||| S:1509 E:1516 ||| NNS
in  ||| S:1516 E:1519 ||| IN
doses  ||| S:1519 E:1525 ||| NNS
of  ||| S:1525 E:1528 ||| IN
about  ||| S:1528 E:1534 ||| IN
80-100  ||| S:1534 E:1541 ||| CD
mg ||| S:1541 E:1543 ||| CD
/ ||| S:1543 E:1544 ||| CD
day ||| S:1544 E:1547 ||| NN
.  ||| S:1547 E:1549 ||| .
Excellent  ||| S:1549 E:1559 ||| JJ
studies  ||| S:1559 E:1567 ||| NNS
have  ||| S:1567 E:1572 ||| VBP
been  ||| S:1572 E:1577 ||| VBN
conducted  ||| S:1577 E:1587 ||| VBN
on  ||| S:1587 E:1590 ||| IN
the  ||| S:1590 E:1594 ||| DT
cognitive-behavioural  ||| S:1594 E:1616 ||| JJ
treatment  ||| S:1616 E:1626 ||| NN
of  ||| S:1626 E:1629 ||| IN
adults  ||| S:1629 E:1636 ||| NNS
with  ||| S:1636 E:1641 ||| IN
ADHD ||| S:1641 E:1645 ||| NNP
,  ||| S:1645 E:1647 ||| ,
the  ||| S:1647 E:1651 ||| DT
results  ||| S:1651 E:1659 ||| NNS
of  ||| S:1659 E:1662 ||| IN
which  ||| S:1662 E:1668 ||| WDT
highlight  ||| S:1668 E:1678 ||| VBD
its  ||| S:1678 E:1682 ||| PRP$
effectiveness  ||| S:1682 E:1696 ||| NN
in  ||| S:1696 E:1699 ||| IN
both  ||| S:1699 E:1704 ||| PDT
the  ||| S:1704 E:1708 ||| DT
short  ||| S:1708 E:1714 ||| JJ
and  ||| S:1714 E:1718 ||| CC
the  ||| S:1718 E:1722 ||| DT
long  ||| S:1722 E:1727 ||| JJ
term ||| S:1727 E:1731 ||| NN
.  ||| S:1731 E:1733 ||| .
